Use of local estrogenotherapy in urology and pelviperineology: A systematic review;Œstrogénothérapie locale en urologie et pelvi-périnéologie. Revue de littérature

Progres en Urologie

Volumn 25, Issue 11, 2015, Pages 628-635

  Benoit, T ^a   Leguevaque, P ^a   Roumiguie M ^a   Beauval, J B ^a   Malavaud, B ^a   Soulie M ^a   Rischmann, P ^a   Gourdy, P ^a   Arnal, J F ^a   Game, X ^a  

^a CHU RANGUEIL   (France)

Author keywords

Cancer; Dyspareunia; Thrombosis; Urinary incontinence; Urinary infection; Vaginal estrogen

Indexed keywords

ESTROGEN;

FEMALE; HUMAN; MENOPAUSE; TOPICAL DRUG ADMINISTRATION; URINARY INCONTINENCE; URINARY TRACT INFECTIONS;

ADMINISTRATION, TOPICAL; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; URINARY INCONTINENCE; URINARY TRACT INFECTIONS;

EID: 84941315325     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2015.01.012     Document Type: Short Survey

References (48)

1. Robinson D., Toozs-Hobson P., Cardozo L. The effect of hormones on the lower urinary tract. Menopause Int 2013, 19:155-162.
2. Game X., Rischmann P., Arnal J.F., Malavaud B. Role of estrogens in lower urinary tract physiology and physiopathology. Prog Urol 2013, 23:502-510.
3. Portman D.J., Gass M.L., Vulvovaginal Atrophy Terminology Consensus Conference P. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. J Sex Med 2014, 11:2865-2872.
4. Nappi R.E., Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA) - results from an international survey. Climacteric 2012, 15:36-44.
5. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
6. Monane M., Gurwitz J.H., Lipsitz L.A., Glynn R.J., Choodnovskiy I., Avorn J. Epidemiologic and diagnostic aspects of bacteriuria: a longitudinal study in older women. J Am Geriatr Soc 1995, 43:618-622.
7. Wang C., Symington J.W., Ma E., Cao B., Mysorekar I.U. Estrogenic modulation of uropathogenic Escherichia coli infection pathogenesis in a murine menopause model. Infect Immun 2013, 81:733-739.
8. Luthje P., Brauner H., Ramos N.L., Ovregaard A., Glaser R., Hirschberg A.L., et al. Estrogen supports urothelial defense mechanisms. Sci Transl Med 2013, 5:190ra80.
9. Han J.H., Kim M.S., Lee M.Y., Kim T.H., Lee M.K., Kim H.R., et al. Modulation of human beta-defensin-2 expression by 17-beta-estradiol and progesterone in vaginal epithelial cells. Cytokine 2010, 49:209-214.
10. Anand M., Wang C., French J., Isaacson-Schmid M., Wall L.L., Mysorekar I.U. Estrogen affects the glycosaminoglycan layer of the murine bladder. Female Pelvic Med Reconstr Surg 2012, 18:148-152.
11. Raz R., Stamm W.E. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993, 329:753-756.
12. Eschenbach D.A., Davick P.R., Williams B.L., Klebanoff S.J., Young-Smith K., Critchlow C.M., et al. Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol 1989, 27:251-256.
13. Chan R.C., Reid G., Irvin R.T., Bruce A.W., Costerton J.W. Competitive exclusion of uropathogens from human uroepithelial cells by Lactobacillus whole cells and cell wall fragments. Infect Immun 1985, 47:84-89.
14. Eriksen B., randomized A. open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 1999, 180:1072-1079.
15. Perrotta C., Aznar M., Mejia R., Albert X., Ng C.W. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev 2008, CD005131.
16. Beerepoot M.A., Geerlings S.E., van Haarst E.P., van Charante N.M., ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol 2013, 190:1981-1989.
17. Sherburn M., Guthrie J.R., Dudley E.C., O'Connell H.E., Dennerstein L. Is incontinence associated with menopause?. Obstet Gynecol 2001, 98:628-633.
18. Townsend M.K., Danforth K.N., Lifford K.L., Rosner B., Curhan G.C., Resnick N.M., et al. Incidence and remission of urinary incontinence in middle-aged women. Am J Obstet Gynecol 2007, 197:167. [e1-5].
19. Waetjen L.E., Ye J., Feng W.Y., Johnson W.O., Greendale G.A., Sampselle C.M., et al. Association between menopausal transition stages and developing urinary incontinence. Obstet Gynecol 2009, 114:989-998.
20. Zhu L., Lang J., Liu C., Han S., Huang J., Li X. The epidemiological study of women with urinary incontinence and risk factors for stress urinary incontinence in China. Menopause 2009, 16:831-836.
21. Augsburger H.R., Fuhrer C. Immunohistochemical analysis of estrogen receptors in the urethra of sexually intact, ovariectomized, and estrogen-substituted ovariectomized sheep. Int Urogynecol J 2014, 25:657-662.
22. Taylor A.H., Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol 2000, 24:145-155.
23. Game X., Allard J., Escourrou G., Gourdy P., Tack I., Rischmann P., et al. Estradiol increases urethral tone through the local inhibition of neuronal nitric oxide synthase expression. Am J Physiol Regul Integr Comp Physiol 2008, 294:R851-R857.
24. Hextall A. Oestrogens and lower urinary tract function. Maturitas 2000, 36:83-92.
25. Chen Y.H., Chen C.J., Yeh S., Lin Y.N., Wu Y.C., Hsieh W.T., et al. Urethral dysfunction in female mice with estrogen receptor beta deficiency. PloS One 2014, 9:e109058.
26. Yoshida J., Aikawa K., Yoshimura Y., Shishido K., Yanagida T., Yamaguchi O. The effects of ovariectomy and estrogen replacement on acetylcholine release from nerve fibres and passive stretch-induced acetylcholine release in female rat bladder. Neurourol Urodyn 2007, 26:1050-1055.
27. Yu Y., Shen Z., Zhou X., Chen S. Effects of steroid hormones on morphology and vascular endothelial growth factor expression in female bladder. Urology 2009, 73:1210-1217.
28. Simunic V., Banovic I., Ciglar S., Jeren L., Pavicic Baldani D., Sprem M. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet 2003, 82:187-197.
29. Cody J.D., Jacobs M.L., Richardson K., Moehrer B., Hextall A. Oestrogen therapy for urinary incontinence in postmenopausal women. Cochrane Database Syst Rev 2012, 10:CD001405.
30. Robinson D., Cardozo L., Milsom I., Pons M.E., Kirby M., Koelbl H., et al. Oestrogens and overactive bladder. Neurourol Urodyn 2014, 33:1086-1091.
31. Traish A.M., Botchevar E., Kim N.N. Biochemical factors modulating female genital sexual arousal physiology. J Sex Med 2010, 7:2925-2946.
32. Nappi R.E., Kingsberg S., Maamari R., Simon J. The CLOSER (CLarifying Vaginal Atrophy's Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med 2013, 10:2232-2241.
33. Suckling J., Lethaby A., Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006, CD001500.
34. Simon J., Nachtigall L., Gut R., Lang E., Archer D.F., Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008, 112:1053-1060.
35. Casper F., Petri E., Vaginal Ring Study Group Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Int Urogynecol J Pelvic Floor Dysfunct 1999, 10:171-176.
36. Long C.Y., Liu C.M., Hsu S.C., Wu C.H., Wang C.L., Tsai E.M. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 2006, 13:737-743.
37. Bygdeman M., Swahn M.L. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996, 23:259-263.
38. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013, 20:888-902. [quiz 3-4].
39. Santen R.J. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 2014, 1-14. [Epub ahead of print].
40. Rahn D.D., Carberry C., Sanses T.V., Mamik M.M., Ward R.M., Meriwether K.V., et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014, 124:1147-1156.
41. Schmidt G., Andersson S.B., Nordle O., Johansson C.J., Gunnarsson P.O. Release of 17-beta-oestradiol from a vaginal ring in postmenopausal women: pharmacokinetic evaluation. Gynecol Obstet Invest 1994, 38:253-260.
42. Baumgart J., Nilsson K., Evers A.S., Kallak T.K., Poromaa I.S. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 2013, 20:162-168.
43. Le Ray I., Dell'Aniello S., Bonnetain F., Azoulay L., Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat 2012, 135:603-609.
44. Moegele M., Buchholz S., Seitz S., Ortmann O. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet 2012, 285:1397-1402.
45. Diller M., Schuler S., Buchholz S., Lattrich C., Treeck O., Ortmann O. Effects of estriol on growth, gene expression and estrogen response element activation in human breast cancer cell lines. Maturitas 2014, 77:336-343.
46. Ulrich L.S., Naessen T., Elia D., Goldstein J.A., Eugster-Hausmann M., investigators VAGt Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. Climacteric 2010, 13:228-237.
47. Simon J., Nachtigall L., Ulrich L.G., Eugster-Hausmann M., Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010, 116:876-883.
48. Sitruk-Ware R., Plu-Bureau G., Menard J., Conard J., Kumar S., Thalabard J.C., et al. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab 2007, 92:2074-2079.